Research and Markets: The New Trends of Drug Development Outsourcing in China and India 2012

Research and Markets: The New Trends of Drug Development Outsourcing in China and India 2012

<0> Research and MarketsLaura Wood, Senior ManagerU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

The rises of China and India as two key emerging markets provide enormous opportunities to both multinational drug companies and professional outsourcing service providers. However, there are significant differences between these two countries, in particular in the areas related to drug R&D, which makes each country unique for certain types of outsourcing activities. Although multinational drug companies now could have more choices than ever before, China and India each actually play different roles in global pharma outsourcing industry in general and in drug development service in specific.

To all global drug companies that are interested in conducting clinical trials in either one of these two countries, the key is to understand the strengths and weaknesses of the local pharmaceutical and biotech industries, the social and cultural differences, the cost structures, and the general industrial infrastructure of each country, as well as their advantages and disadvantages for a specific development project, before they are able to decide which country is best suitable for what projects.

The report is a must-read book to all global pharmaceutical, biotechnology, financial investment and outsourcing service companies that are interested in having a best position in either one of these two countries. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of the pharmaceutical industry in their own countries.

Scope of the Report

Executive Summary

- China and India: The two key emerging players of global drug R&D outsourcing

- Current experiences of Chinese and Indian companies in innovative drug R&D

- The new trends of clinical development outsourcing in China and India

- Analysis of best strategies for drug development outsourcing in China and India

Chapter One - China and India: The Two Key Emerging Players of Global Drug R&D Outsourcing

1.1. Introduction

1.2. Current trends of global drug R&D outsourcing

1.3. China and India: The two key pharmamerging markets

1.4 China and India possess unique features attracting global pharma companies for outsourcing

1.5 Latest R&D activities of major pharma companies in China and India

1.6 Current states of Chinese and Indian CRO industries

Chapter Two - Current Experiences of Chinese and Indian Companies in Innovative Drug R&D

2.1 Introduction

2.2 Current states of biotechnology industry in China and India

2.3 Current states of innovative drug R&D in China and India

2.4 Current states and capabilities of biologic drug R&D in China and India

2.5 Key domestic players in China and India and their pipelines of innovative drugs

Chapter Three - The New Trends of Clinical Development Outsourcing in China and India

3.1 Introduction

3.2 Latest trends of global clinical trial outsourcing

3.3 Current competitive landscape and market sizes of clinical development services in China and India

3.4 Current regulatory states of clinical trial in China and India

3.5 Current service capabilities and key players of Chinese and Indian CROs in clinical trial services

3.6 Multinational drug companies outsourcing clinical trials to China and India-Current development trends

3.7 Growth potentials of Chinese and Indian clinical trial service markets ? Future outlook

3.8 Current states of bioanalytical services in China and India

Chapter Four - Analysis of Best Strategies for Drug Development Outsourcing in China and India

4.1 Introduction

4.2 General comparisons of pharmaceutical industry between China and India

4.3 Comparisons of biotechnology industry between China and India and in-depth analysis of their future development prospects

4.4 Comparison of innovative drug R&D between China and India and in-depth analysis of their future development prospects

4.5 In-depth analyses and comparisons of drug development outsourcing service industry between China and India

4.6 Analysis of different R&D strategies of major pharma companies in China and India

4.7 Analysis of different outsourcing strategies of major pharma companies in China and India

4.8 Comparison of future growth potentials of CRO markets between China and India

4.9 Analysis of future growth obstacles of Chinese and Indian clinical development service industries

Appendix

Appendix I. Research Methodology

Appendix II. About JZMed, Inc.

List of Tables

List of Figures

List of Case Studies

For more information visit

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.